Most Read

Deciphera president and CEO Dr Michael Taylor said: “We are extremely pleased with the recent progress made on our rebastinib program, including today’s announcement that we have initiated

The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS. Pursuant to the terms of the settlement, Ironwood and Allergan

Nuvo’s president and CEO Jesse Ledger said: “The close of this transaction positions Nuvo as one of the premier specialty pharmaceutical companies in Canada. “Nuvo is now truly

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was initially approved on May 3, 2018 under the FDA’s Accelerated Approval pathway. It is the

The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will

The new facility, which is strategically located in close vicinity to the Ljubljana Airport, will carry out the distribution of finished products worldwide and will be used for

Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent

Under the terms of the agreement, Innovare will use DelSiTech’s technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). DelSiTech is

MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via